We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Review · January 22, 2021

Oral Semaglutide in Patients With T2DM

Diabetes Research and Clinical Practice


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Research and Clinical Practice
Efficacy and Safety of the Glucagon-Like Peptide-1 Receptor Agonist Oral Semaglutide in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Diabetes Res. Clin. Pract. 2021 Jan 09;[EPub Ahead of Print], J Li, K He, J Ge, C Li, Z Jing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading